Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
Gamucci T, Mentuccia L, Natoli C, Sperduti I, Cassano A, Michelotti A, Di Lauro L, Sergi D, Fabi A, Sarobba MG, Marchetti P, Barba M, Magnolfi E, Maugeri-Saccà M, Rossi E, Sini V, Grassadonia A, Pellegrini D, Astone A, Nisticò C, Angelini F, Vaccaro A, Pellegrino A, De Angelis C, Palleschi M, Moscetti L, Bertolini I, Buglioni S, Giordano A, Pizzuti L, Vici P. Gamucci T, et al. Among authors: sergi d. J Cell Physiol. 2017 Jun;232(6):1571-1578. doi: 10.1002/jcp.25685. Epub 2016 Nov 30. J Cell Physiol. 2017. PMID: 27861874 Free PMC article.
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
Vici P, Pizzuti L, Natoli C, Moscetti L, Mentuccia L, Vaccaro A, Sergi D, Di Lauro L, Trenta P, Seminara P, Santini D, Iezzi L, Tinari N, Bertolini I, Sini V, Mottolese M, Giannarelli D, Giotta F, Maugeri-Saccà M, Barba M, Marchetti P, Michelotti A, Sperduti I, Gamucci T. Vici P, et al. Among authors: sergi d. Breast Cancer Res Treat. 2014 Oct;147(3):599-607. doi: 10.1007/s10549-014-3133-1. Epub 2014 Sep 19. Breast Cancer Res Treat. 2014. PMID: 25234842 Free PMC article. Clinical Trial.
Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer.
Vici P, Crispo A, Giordano A, Di Lauro L, Sperati F, Terrenato I, Pizzuti L, Sergi D, Mottolese M, Botti C, Grimaldi M, Capasso I, D'Aiuto G, Di Bonito M, Di Paola F, Maugeri-Saccà M, Montella M, Barba M. Vici P, et al. Among authors: d aiuto g, sergi d. J Cell Physiol. 2015 Aug;230(8):1708-12. doi: 10.1002/jcp.24891. J Cell Physiol. 2015. PMID: 25510909
Triple positive breast cancer: a distinct subtype?
Vici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, Barba M, Sergi D, Botti C, Michelotti A, Moscetti L, Mariani L, Izzo F, D'Onofrio L, Sperduti I, Conti F, Rossi V, Cassano A, Maugeri-Saccà M, Mottolese M, Marchetti P. Vici P, et al. Among authors: d onofrio l, sergi d. Cancer Treat Rev. 2015 Feb;41(2):69-76. doi: 10.1016/j.ctrv.2014.12.005. Epub 2014 Dec 19. Cancer Treat Rev. 2015. PMID: 25554445 Free article. Review.
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.
Barba M, Pizzuti L, Sperduti I, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Izzo F, Rinaldi M, Mentuccia L, Vaccaro A, Iezzi L, Grassadonia A, Michelotti A, Landucci E, Perracchio L, Pescarmona E, Di Filippo F, Giordano A, Maugeri-Saccà M, Vici P. Barba M, et al. Among authors: sergi d. J Cell Physiol. 2016 May;231(5):986-91. doi: 10.1002/jcp.25213. Epub 2015 Nov 20. J Cell Physiol. 2016. PMID: 26449308
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.
Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F. Vici P, et al. Among authors: d onofrio l, sergi d. Oncotarget. 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480. Oncotarget. 2016. PMID: 26910921 Free PMC article.
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.
Pizzuti L, Barba M, Giannarelli D, Sergi D, Botti C, Marchetti P, Anzà M, Maugeri-Saccà M, Natoli C, Di Filippo S, Catenaro T, Tomao F, Amodio A, Carpano S, Perracchio L, Mottolese M, Di Lauro L, Sanguineti G, Di Benedetto A, Giordano A, Vici P. Pizzuti L, et al. Among authors: sergi d. J Cell Physiol. 2016 Nov;231(11):2541-7. doi: 10.1002/jcp.25432. Epub 2016 Jun 2. J Cell Physiol. 2016. PMID: 27187274 Free PMC article. Clinical Trial.
216 results